Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 188

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Next-generation probiotics: the upcoming biotherapeutics

Open access
Al-Fakhrany, Omnia Momtaz, Elekhnawy, Engy · 2024 · Molecular Biology Reports

Abstract

Recent and continuing advances in gut microbiome research have pointed out the role of the gut microbiota as an unexplored source of potentially beneficial probiotic microbes. Along the lines of these advances, both public awareness and acceptance of probiotics are increasing. That’s why; academic and industrial research is dedicated to identifying and investigating new microbial strains for the development of next-generation probiotics (NGPs). At this time, there is a growing interest in NGPs as biotherapeutics that alter the gut microbiome and affect various diseases development. In this work, we have focused on some emergent and promising NGPs, specifically Eubacterium hallii, Faecalibacterium prausnitzii, Roseburia spp., Akkermansia muciniphila, and Bacteroides fragilis, as their presence in the gut can have an impact on the development of various diseases. Emerging studies point out the beneficial roles of these NGPs and open up novel promising therapeutic options. Interestingly, these NGPs were found to enhance gastrointestinal immunity, enhance immunotherapy efficacy in cancer patients, retain the intestinal barrier integrity, generate valuable metabolites, especially short-chain fatty acids, and decrease complications of chemotherapy and radiotherapy. Although many of these NGPs are considered promising for the prevention and treatment of several chronic diseases, research on humans is still lacking. Therefore, approval of these microbes from regulatory agencies is rare. Besides, some issues limit their wide use in the market, such as suitable methods for the culture and storage of these oxygen-sensitive microbes. The present review goes over the main points related to NGPs and gives a viewpoint on the key issues that still hinder their wide application. Furthermore, we have focused on the advancement in NGPs and human healthiness investigations by clarifying the limitations of traditional probiotic microorganisms, discussing the characteristics of emerging NGPs and defining their role in the management of certain ailments. Future research should emphasize the isolation, mechanisms of action of these probiotics, safety, and clinical efficacy in humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11033-024-09398-5

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 78

  1. Silva DR, Sardi JdCO, de Souza Pitangui N, Roque SM, da Silva ACB, Rosalen PL (2020) Probiotics as an alternative antimicrobial therapy: current reality and future directions. J Funct Foods 73:104080 · DOI · Paper page
  2. Canfora EE, Meex RC, Venema K, Blaak EE (2019) Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Reviews Endocrinol 15(5):261–273 · DOI · Paper page
  3. Liu B-N, Liu X-T, Liang Z-H, Wang J-H (2021) Gut microbiota in obesity. World J Gastroenterol 27(25):3837 · DOI · Paper page
  4. Mejía-Caballero A, Salas-Villagrán VA, Jiménez-Serna A, Farrés A (2021) Challenges in the production and use of probiotics as therapeuticals in cancer treatment or prevention. J Ind Microbiol Biotechnol 48(9–10):kuab052 · DOI
  5. Heinken A, Khan MT, Paglia G, Rodionov DA, Harmsen HJ, Thiele I (2014) Functional metabolic map of Faecalibacterium prausnitzii, a beneficial human gut microbe. J Bacteriol 196(18):3289–3302 · DOI · Paper page
  6. Elekhnawy E, Negm WA (2022) The potential application of probiotics for the prevention and treatment of COVID-19. Egypt J Med Hum Genet 23(1):1–9 · DOI
  7. Sun F, Zhang Q, Zhao J, Zhang H, Zhai Q, Chen W (2019) A potential species of next-generation probiotics? The dark and light sides of Bacteroides fragilis in health. Food Res Int 126:108590 · DOI
  8. De Filippis F, Esposito A, Ercolini D (2022) Outlook on next-generation probiotics from the human gut. Cell Mol Life Sci 79(2):76 · DOI
  9. Bottari B, Castellone V, Neviani E, Probiotics, COVID-19 (2021) Int J Food Sci Nutr 72(3):293–299 · DOI
  10. Sankarapandian V, Venmathi Maran BA, Rajendran RL, Jogalekar MP, Gurunagarajan S, Krishnamoorthy R, Gangadaran P, Ahn B-C (2022) An update on the effectiveness of Probiotics in the Prevention and Treatment of Cancer. Life 12(1):59 · DOI
  11. Morelli L, Capurso L (2012) FAO/WHO guidelines on probiotics: 10 years later. J Clin Gastroenterol 46:S1–S2 · DOI · Paper page
  12. Jahanshahi M, Maleki Dana P, Badehnoosh B, Asemi Z, Hallajzadeh J, Mansournia MA, Yousefi B, Moazzami B, Chaichian S (2020) Anti-tumor activities of probiotics in cervical cancer. J Ovarian Res 13(1):1–11 · DOI
  13. Cunningham M, Azcarate-Peril MA, Barnard A, Benoit V, Grimaldi R, Guyonnet D, Holscher HD, Hunter K, Manurung S, Obis D (2021) Shaping the future of probiotics and prebiotics. Trends Microbiol 29(8):667–685 · DOI · Paper page
  14. Singh K, Rao A, Probiotics (2021) A potential immunomodulator in COVID-19 infection management. Nutr Res 87:1–12 · DOI
  15. Sionek B, Szydłowska A, Zielińska D, Neffe-Skocińska K, Kołożyn-Krajewska D (2023) Beneficial Bacteria isolated from Food in Relation to the Next Generation of Probiotics. Microorganisms 11(7):1714 · DOI
  16. Martín R, Langella P (2019) Emerging health concepts in the probiotics field: streamlining the definitions. Front Microbiol 10:1047 · DOI · Paper page
  17. Olveira G, González-Molero I (2016) An update on probiotics, prebiotics and symbiotics in clinical nutrition. Endocrinología Y Nutrición (English Edition) 63(9):482–494 · DOI
  18. Tan H, Zhai Q, Chen W (2019) Investigations of Bacteroides spp. towards next-generation probiotics. Food Res Int 116:637–644 · DOI · Paper page
  19. Han W, Zhuang X (2021) Research progress on the next-generation probiotic Akkermansia muciniphila in the intestine. Food Front 2(4):443–448 · DOI
  20. de Pereira M, de Oliveira Coelho GV, Júnior B, Thomaz-Soccol AIM, Soccol V (2018) How to select a probiotic? A review and update of methods and criteria. Biotechnol Adv 36(8):2060–2076 · DOI · Paper page
  21. Chen D, Jin D, Huang S, Wu J, Xu M, Liu T, Dong W, Liu X, Wang S, Zhong W (2020) Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating wnt signaling and gut microbiota. Cancer Lett 469:456–467 · DOI · Paper page
  22. Kaźmierczak-Siedlecka K, Skonieczna-Żydecka K, Hupp T, Duchnowska R, Marek-Trzonkowska N, Połom K (2022) Next-generation probiotics–do they open new therapeutic strategies for cancer patients? Gut Microbes 14(1):2035659 · DOI
  23. Husted AS, Trauelsen M, Rudenko O, Hjorth SA, Schwartz TW (2017) GPCR-mediated signaling of metabolites. Cell Metabol 25(4):777–796 · DOI · Paper page
  24. Byndloss MX, Olsan EE, Rivera-Chávez F, Tiffany CR, Cevallos SA, Lokken KL, Torres TP, Byndloss AJ, Faber F, Gao Y (2017) Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science 357(6351):570–575 · DOI · Paper page
  25. García-Velasco JA, Menabrito M, Catalán IB (2017) What fertility specialists should know about the vaginal microbiome: a review. Reprod Biomed Online 35(1):103–112 · DOI
  26. Deng H, Yang S, Zhang Y, Qian K, Zhang Z, Liu Y, Wang Y, Bai Y, Fan H, Zhao X (2018) Bacteroides fragilis prevents Clostridium difficile infection in a mouse model by restoring gut barrier and microbiome regulation. Front Microbiol 9:2976 · DOI
  27. Hu W, Gao W, Liu Z, Fang Z, Zhao J, Zhang H, Lu W, Chen W (2022) Biodiversity and physiological characteristics of novel Faecalibacterium prausnitzii strains isolated from human feces. Microorganisms 10(2):297 · DOI
  28. Aschard H, Laville V, Tchetgen ET, Knights D, Imhann F, Seksik P, Zaitlen N, Silverberg MS, Cosnes J, Weersma RK (2019) Genetic effects on the commensal microbiota in inflammatory bowel disease patients. PLoS Genet 15, (3), e1008018 · DOI
  29. Díaz-Rizzolo DA, Kostov B, López-Siles M, Serra A, Colungo C, González-de-Paz L, Martinez-Medina M, Sisó-Almirall A, Gomis R (2020) Healthy dietary pattern and their corresponding gut microbiota profile are linked to a lower risk of type 2 diabetes, independent of the presence of obesity. Clin Nutr 39(2):524–532 · DOI
  30. Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R, Ginanni Corradini S, Nobili V, De Peppo F (2018) Gut microbiota markers in obese adolescent and adult patients: age-dependent differential patterns. Front Microbiol 9:1210 · DOI · Paper page
  31. Martín R, Miquel S, Benevides L, Bridonneau C, Robert V, Hudault S, Chain F, Berteau O, Azevedo V, Chatel JM (2017) Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. Prausnitzii as a next-generation probiotic. Front Microbiol 8:1226 · DOI · Paper page
  32. Duncan SH, Aminov RI, Scott KP, Louis P, Stanton TB, Flint HJ (2006) Proposal of Roseburia faecis sp. nov., Roseburia hominis sp. nov. and Roseburia inulinivorans sp. nov., based on isolates from human faeces. Int J Syst Evol MicroBiol 56(10):2437–2441 · DOI · Paper page
  33. Wagner VE, Dey N, Guruge J, Hsiao A, Ahern PP, Semenkovich NP, Blanton LV, Cheng J, Griffin N, Stappenbeck TS (2016) Effects of a gut pathobiont in a gnotobiotic mouse model of childhood undernutrition. Science translational medicine 8, (366), 366ra164-366ra164 · DOI
  34. Vernay T, Cannie I, Gaboriau F, Gall SD-L, Tamanai-Shacoori Z, Burel A, Jolivet-Gougeon A, Loréal O, Bousarghin L (2020) Bacteroides fragilis prevents Salmonella Heidelberg translocation in co-culture model mimicking intestinal epithelium. Beneficial Microbes 11(4):391–401 · DOI
  35. Chatzidaki-Livanis M, Coyne MJ, Comstock LE (2014) An antimicrobial protein of the gut symbiont B acteroides fragilis with a MACPF domain of host immune proteins. Mol Microbiol 94(6):1361–1374 · DOI
  36. Ennamorati M, Vasudevan C, Clerkin K, Halvorsen S, Verma S, Ibrahim S, Prosper S, Porter C, Yeliseyev V, Kim M (2020) Intestinal microbes influence development of thymic lymphocytes in early life. Proc Natl Acad Sci 117(5):2570–2578 · DOI
  37. Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, Flint HJ (2000) Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol 66(4):1654–1661 · DOI · Paper page
  38. Pham VT, Lacroix C, Braegger CP, Chassard C (2016) Early colonization of functional groups of microbes in the infant gut. Environ Microbiol 18(7):2246–2258 · DOI
  39. Schwab C, Ruscheweyh H-J, Bunesova V, Pham VT, Beerenwinkel N, Lacroix C (2017) Trophic interactions of infant bifidobacteria and Eubacterium hallii during L-fucose and fucosyllactose degradation. Front Microbiol 8:95 · DOI · Paper page
  40. Hussein LA (2022) Novel prebiotics and next-generation probiotics: opportunities and challenges. Funct Foods Nutraceuticals Metabolic Non-Communicable Dis 431–457 · DOI
  41. Udayappan S, Manneras-Holm L, Chaplin-Scott A, Belzer C, Herrema H, Dallinga-Thie GM, Duncan SH, Stroes ES, Groen AK, Flint HJ (2016) Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice. NPJ Biofilms Microbiomes 2(1):1–10 · DOI · Paper page
  42. Maguire M, Maguire G (2017) The role of microbiota, and probiotics and prebiotics in skin health. Arch Dermatol Res 309(6):411–421 · DOI
  43. Miquel S, Martin R, Rossi O, Bermúdez-Humarán L, Chatel J, Sokol H, Thomas M, Wells J, Langella P (2013) Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol 16(3):255–261 · DOI · Paper page
  44. Cani PD, de Vos WM (2017) Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front Microbiol 8:1765 · DOI · Paper page
  45. Fekry MI, Engels C, Zhang J, Schwab C, Lacroix C, Sturla SJ, Chassard C (2016) The strict anaerobic gut microbe Eubacterium hallii transforms the carcinogenic dietary heterocyclic amine 2-amino‐1‐methyl‐6‐phenylimidazo [4, 5‐b] pyridine (PhIP). Environ Microbiol Rep 8(2):201–209 · DOI
  46. Mukherjee A, Lordan C, Ross RP, Cotter PD (2020) Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health. Gut Microbes 12(1):1802866 · DOI · Paper page
  47. Hasan Khudhair D, Al-Gareeb AI, Al-Kuraishy HM, El-Kadem AH, Elekhnawy E, Negm WA, Saber S, Cavalu S, Tirla A, Alotaibi SS (2022) Combination of vitamin C and curcumin safeguards against methotrexate-induced acute liver injury in mice by synergistic antioxidant effects. Front Med 9:866343 · DOI
  48. Oh S-H, Kim IS, Kim GI, Kim JA, Moon YS, Jang JC, Lee SS, Jung JH, Park J, Cho KK (2022) Intestinal microbial composition changes induced by Lactobacillus plantarum GBL 16, 17 fermented feed and intestinal immune homeostasis regulation in pigs. J Anim Sci Technol 64(6):1184 · DOI
  49. Lagier J-C, Hugon P, Khelaifia S, Fournier P-E, La Scola B, Raoult D (2015) The rebirth of culture in microbiology through the example of culturomics to study human gut microbiota. Clin Microbiol Rev 28(1):237–264 · DOI · Paper page
  50. Kasahara K, Krautkramer KA, Org E, Romano KA, Kerby RL, Vivas EI, Mehrabian M, Denu JM, Bäckhed F, Lusis AJ (2018) Interactions between Roseburia intestinalis and diet modulate atherogenesis in a murine model. Nat Microbiol 3(12):1461–1471 · DOI · Paper page
  51. Seo B, Jeon K, Moon S, Lee K, Kim W-K, Jeong H, Cha KH, Lim MY, Kang W, Kweon M-N (2020) Roseburia spp. abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice. Cell Host Microbe 27(1):25–40 e6 · DOI · Paper page
  52. Wu X, Pan S, Luo W, Shen Z, Meng X, Xiao M, Tan B, Nie K, Tong T, Wang X (2020) Roseburia intestinalis–derived flagellin ameliorates colitis by targeting miR–223–3p–mediated activation of NLRP3 inflammasome and pyroptosis. Mol Med Rep 22(4):2695–2704
  53. Attallah NG, Negm WA, Elekhnawy E, Altwaijry N, Elmongy EI, El-Masry TA, Alturki EA, Yousef DA, Shoukheba Y (2021) Antibacterial activity of Boswellia sacra Flueck. Oleoresin extract against Porphyromonas gingivalis periodontal pathogen. Antibiotics 10(7):859 · DOI
  54. Alotaibi B, Negm WA, Elekhnawy E, El-Masry TA, Elharty ME, Saleh A, Abdelkader DH, Mokhtar FA (2022) Antibacterial activity of nano zinc oxide green-synthesised from Gardenia Thailandica triveng. Leaves against Pseudomonas aeruginosa clinical isolates: in vitro and in vivo study. Artif Cells Nanomed Biotechnol 50(1):96–106 · doi:10.1080/21691401.2022.2056191
  55. Lin T-L, Shu C-C, Lai W-F, Tzeng C-M, Lai H-C, Lu C-C (2019) Investiture of next generation probiotics on amelioration of diseases–strains do matter. Med Microecology 1:100002 · DOI
  56. Quévrain E, Maubert M, Michon C, Chain F, Marquant R, Tailhades J, Miquel S, Carlier L, Bermúdez-Humarán L, Pigneur B (2016) Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut 65(3):415–425 · DOI · Paper page
  57. Miyaoka T, Kanayama M, Wake R, Hashioka S, Hayashida M, Nagahama M, Okazaki S, Yamashita S, Miura S, Miki H (2018) Clostridium butyricum MIYAIRI 588 as adjunctive therapy for treatment-resistant major depressive disorder: a prospective open-label trial. Clin Neuropharmacol 41(5):151–155 · DOI · Paper page
  58. Fakruddin M, Hossain MN, Ahmed MM (2017) Antimicrobial and antioxidant activities of Saccharomyces cerevisiae IFST062013, a potential probiotic. BMC Complement Altern Med 17:1–11 · DOI · Paper page
  59. Alotaibi B, Mokhtar FA, El-Masry TA, Elekhnawy E, Mostafa SA, Abdelkader DH, Elharty ME, Saleh A, Negm WA (2021) Antimicrobial activity of brassica rapa L. flowers extract on gastrointestinal tract infections and antiulcer potential against Indomethacin-Induced gastric ulcer in rats supported by metabolomics profiling. J Inflamm Res 14:7411 · DOI
  60. Celiberto LS, Pinto RA, Rossi EA, Vallance BA, Cavallini DC (2018) Isolation and characterization of potentially probiotic bacterial strains from mice: Proof of concept for personalized probiotics. Nutrients 10(11):1684 · DOI
  61. Zhang H, Duan Y, Cai F, Cao D, Wang L, Qiao Z, Hong Q, Li N, Zheng Y, Su M (2022) Next-Generation Probiotics: Microflora Intervention to Human Diseases. BioMed Research International 2022 · DOI
  62. El-Banna T, Abd El-Aziz A, Sonbol F, El-Ekhnawy E (2019) Adaptation of Pseudomonas aeruginosa clinical isolates to benzalkonium chloride retards its growth and enhances biofilm production. Mol Biol Rep 46:3437–3443 · DOI
  63. Attallah NG, El-Sherbeni SA, El-Kadem AH, Elekhnawy E, El-Masry TA, Elmongy EI, Altwaijry N, Negm W (2022) A., elucidation of the metabolite profile of Yucca gigantea and assessment of its cytotoxic, antimicrobial, and anti-inflammatory activities. Molecules 27(4):1329 · doi:10.3390/molecules27041329
  64. Alotaibi B, Negm WA, Elekhnawy E, El-Masry TA, Elseady WS, Saleh A, Alotaibi KN, El-Sherbeni SA (2021) Antibacterial, Immunomodulatory, and Lung Protective Effects of Boswellia dalzielii Oleoresin Ethanol Extract in Pulmonary Diseases: In Vitro and In Vivo Studies. Antibiotics 10, (12), 1444 · DOI
  65. Abdelaziz A, Sonbol F, Elbanna T, El-Ekhnawy E (2019) Exposure to sublethal concentrations of benzalkonium chloride induces antimicrobial resistance and cellular changes in Klebsiellae pneumoniae clinical isolates. Microb Drug Resist 25(5):631–638 · DOI
  66. Attallah NG, Elekhnawy E, Negm WA, Hussein IA, Mokhtar FA, Al-Fakhrany OM (2022) In vivo and in vitro antimicrobial activity of biogenic silver nanoparticles against Staphylococcus aureus clinical isolates. Pharmaceuticals 15(2):194 · DOI
  67. He X, Zhao S, Li Y (2021) Faecalibacterium prausnitzii: A next-generation probiotic in gut disease improvement. Canadian Journal of Infectious Diseases and Medical Microbiology 2021, 1–10 · DOI
  68. Attallah NG, El-Kadem AH, Negm WA, Elekhnawy E, El-Masry TA, Elmongy EI, Altwaijry N, Alanazi AS, Al-Hamoud GA, Ragab AE (2021) Promising antiviral activity of Agrimonia pilosa phytochemicals against severe Acute Respiratory Syndrome Coronavirus 2 supported with in vivo mice study. Pharmaceuticals 14(12):1313 · DOI
  69. Elekhnawy EA, Sonbol FI, Elbanna TE, Abdelaziz AA (2021) Evaluation of the impact of adaptation of Klebsiella pneumoniae clinical isolates to benzalkonium chloride on biofilm formation. Egypt J Med Hum Genet 22(1):1–6 · DOI
  70. d’Ettorre G, Ceccarelli G, Marazzato M, Campagna G, Pinacchio C, Alessandri F, Ruberto F, Rossi G, Celani L, Scagnolari C (2020) Challenges in the management of SARS-CoV2 infection: the role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med 7:389 · DOI · Paper page
  71. Abdelkader DH, Negm WA, Elekhnawy E, Eliwa D, Aldosari BN, Almurshedi AS (2022) Zinc oxide nanoparticles as potential delivery carrier: Green synthesis by Aspergillus Niger endophytic fungus, characterization, and in vitro/in vivo antibacterial activity. Pharmaceuticals 15(9):1057 · DOI
  72. Vallianou NG, Kounatidis D, Tsilingiris D, Panagopoulos F, Christodoulatos GS, Evangelopoulos A, Karampela I, Dalamaga M (2023) The role of next-generation probiotics in obesity and obesity-Associated disorders: current knowledge and future perspectives. Int J Mol Sci 24(7):6755 · DOI
  73. Negm WA, El-Aasr M, Kamer AA, Elekhnawy E (2021) Investigation of the Antibacterial Activity and Efflux Pump Inhibitory Effect of Cycas thouarsii R. Br. Extract against Klebsiella pneumoniae clinical isolates. Pharmaceuticals 14(8):756 · DOI
  74. Dronkers T, Krist L, Van Overveld F, Rijkers G (2018) The ascent of the blessed: Regulatory issues on health effects and health claims for probiotics in Europe and the rest of the world. Beneficial Microbes 9(5):717–723 · DOI
  75. Fijan S (2014) Microorganisms with claimed probiotic properties: an overview of recent literature. Int J Environ Res Public Health 11(5):4745–4767 · DOI · Paper page
  76. Leth ML, Ejby M, Workman C, Ewald DA, Pedersen SS, Sternberg C, Bahl MI, Licht TR, Aachmann FL, Westereng B (2018) Differential bacterial capture and transport preferences facilitate co-growth on dietary xylan in the human gut. Nat Microbiol 3(5):570–580 · DOI · Paper page
  77. Ottman N, Davids M, Suarez-Diez M, Boeren S, Schaap PJ, Martins VA, Smidt H, Belzer C, de Vos WM (2017) Genome-scale model and omics analysis of metabolic capacities of Akkermansia muciniphila reveal a preferential mucin-degrading lifestyle. Applied and environmental microbiology 83, (18), e01014-17 · DOI · Paper page
  78. Rivière A, Gagnon M, Weckx S, Roy D, De Vuyst L (2015) Mutual cross-feeding interactions between Bifidobacterium longum subsp. Longum NCC2705 and Eubacterium rectale ATCC 33656 explain the bifidogenic and butyrogenic effects of arabinoxylan oligosaccharides. Appl Environ Microbiol 81(22):7767–7781 · DOI · Paper page

Cited by

See all 188

Metadata

Authors
Al-Fakhrany, O. M., & Elekhnawy, E.
Venue
Molecular Biology Reports
Published
2024-04-15
Volume
51
Issue
1
Pages
505-505
ISSN
  • 0301-4851 (ISSN-L)
  • 1573-4978
OpenAlex
W4394809656
Cited by
188
References
15
FWCI
21.84
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
Tanta University

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Next-generation probiotics: the upcoming biotherapeutics. https://app.cochat.ai/papers/10.1007/s11033-024-09398-5
The paper
Al-Fakhrany, O. M., & Elekhnawy, E. (2024). Next-generation probiotics: the upcoming biotherapeutics. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-09398-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.